LISDEXAMFETAMINE CAP,ORAL
Clinical Criteria Summary
Continuity of Care Inclusion Criteria
- Veteran is transitioning care from the Department of Defense to VHA
- Medication is safe and clinically appropriate as determined by a VA prescriber using shared decision making
- Medication is indicated for tapering the dose or slowly discontinuing therapy as determined by a VA prescriber using shared decision making
Non-Continuity of Care Exclusion Criteria
- Use with or within 2 weeks of a monoamine oxidase inhibitor (MAOI)
Non-Continuity of Care Inclusion Criteria
- Diagnosis of Binge Eating Disorder (BED), did not respond to, is unable to tolerate an adequate trial of, or has a contraindication to topiramate AND a formulary selective serotonin reuptake inhibitor (SSRI)
- Diagnosis of Attention Deficit Hyperactivity Disorder (ADHD), did not respond to, is unable to tolerate an adequate trial of, or has a contraindication to methylphenidate AND a formulary amphetamine product